Digestive Diseases and Sciences

, Volume 62, Issue 3, pp 739–745 | Cite as

Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13C-Urea Breath Test in Helicobacter pylori-Positive Patients

  • Mayu Takimoto
  • Toshihiko TomitaEmail author
  • Takahisa Yamasaki
  • Shota Fukui
  • Masato Taki
  • Takuya Okugawa
  • Takashi Kondo
  • Tomoaki Kono
  • Katsuyuki Tozawa
  • Eitatsu Arai
  • Yoshio Ohda
  • Tadayuki Oshima
  • Hirokazu Fukui
  • Jiro Watari
  • Hiroto Miwa
Original Article


Background and Aim

Vonoprazan (VPZ) is a new oral potassium-competitive acid blocker that has recently become available. The aim of this study was to investigate the effects of VPZ on the urease activity of H. pylori as measured by the 13C-urea breath test (13C-UBT).

Patients and Methods

A total of 60 patients (26 men, 34 women; mean age 53.2 ± 13.6 years) who were diagnosed as H. pylori-positive were recruited. The patients were randomly allocated to three treatment groups: lansoprazole (LPZ) 30 mg (n = 20), VPZ 20 mg (n = 20) once daily for 3 weeks, or the control group (n = 20). The 13C-UBT was carried out at baseline and after 3 weeks of treatment, and the baseline and after treatment results then compared. Δ13C‰ ≥ 2.5‰ was considered H. pylori-positive.


Four patients failed to complete the medication and were omitted from the analysis; data from the LPZ group (n = 18), VPZ group (n = 18), and control group (n = 20) were analyzed. The control group showed no significant change in 13C-UBT data between baseline and the completion of 3-week treatment (baseline: 26.6 ± 23.0‰, completion: 21.1 ± 13.1‰). The 13C-UBT data at week 3 were significantly decreased in both the VPZ group (baseline: 32.8 ± 22.7‰, completion: 7.6 ± 9.2‰, p = 0.0002) and the LPZ group (baseline: 41.8 ± 33.4‰; completion: 9.6 ± 8.8‰, p = 0.0006) compared to baseline.


VPZ treatment reduced the value of UBT, warning that UBT for patients with VPZ treatment should be evaluated carefully.


Helicobacter pylori Urea breath test Vonoprazan 


Compliance with ethical standards

Conflict of interest



  1. 1.
    Ohara S, Kato M, Asaka M, et al. The Ubit-100 13CO2 infrared analyzer: comparison between infrared analyzer spectrometric analysis and mass spectrometric analysis. Helicobacter. 1998;3:49–53.CrossRefPubMedGoogle Scholar
  2. 2.
    Chey WD, Spybrook M, Carpenter S, et al. Prolong effect of omeprazole on the 14C-urea breath test. Am J Gastroenterol. 1996;91:89–92.PubMedGoogle Scholar
  3. 3.
    Chey WD, Woods M, Scheiman JM, et al. Lansoprazol and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol. 1997;92:446–450.PubMedGoogle Scholar
  4. 4.
    Laine L, Estrada R, Trujillo M, et al. Effect of proton pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med. 1998;129:547–550.CrossRefPubMedGoogle Scholar
  5. 5.
    El-Nujumi A, Hilditch TE, Williams C, et al. Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the[14C]urea breath test. Eurl Gastroenterol Hepatol. 1998;10:759–764.CrossRefGoogle Scholar
  6. 6.
    Connor SJ, Seow F, Ngu MC, et al. The effect of dosing with omeprazole on the accuracy of the 13C-urea breath test in Helicobacter pylori-infected subjects. Aliment Pharmacol Ther. 1999;13:1287–1293.CrossRefPubMedGoogle Scholar
  7. 7.
    Savarino V, Bisso G, Pivari M, et al. Effect of gastric acid suppression on 13C-urea breath test; comparison of ranitidine with omeprazole. Aliment Pharmacol Ther. 2000;14:291–297.CrossRefPubMedGoogle Scholar
  8. 8.
    Chey WD, Chathadi KV, Montague J, et al. Intragastric acidification reduces the occurrence of false-negative urea breath test results in patients taking a proton pump inhibitor. Am J Gastroenterol. 2001;96:1028–1032.CrossRefPubMedGoogle Scholar
  9. 9.
    Murakami K, Sato R, Okimoto T, et al. Influence of anti-ulcer drugs used in Japan on the result of 13C-urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol. 2003;38:937–941.CrossRefPubMedGoogle Scholar
  10. 10.
    Adachi K, Fujishiro H, Mihara T, et al. Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol. 2003;18:168–171.CrossRefPubMedGoogle Scholar
  11. 11.
    Graham DY, Opekun AR, Hammoud F, et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol. 2003;98:1005–1009.CrossRefPubMedGoogle Scholar
  12. 12.
    Chey WD. Proton pump inhibitors and the urea breath test: how long is long enough? Am J Gastroenterol. 1997;92:720–721.PubMedGoogle Scholar
  13. 13.
    Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636–648.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ohara S, Kato M, Saito M, Fukuda S, et al. Comparison between a new 13C-urea breath test, using a film-coated tablet, and the conventional 13C-urea breath test for the detection of Helicobacter pylori infection. J Gastroenterol. 2002;39:621–628.Google Scholar
  15. 15.
    Parente F, Sainaghi M, Sangaletti O, et al. Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test. Aliment Pharmacol Ther. 2002;16:553–557.CrossRefPubMedGoogle Scholar
  16. 16.
    Bravo LE, Realpe JL, Campo C, et al. Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection. Am J Gastroenterol. 1999;94:2380–2383.CrossRefPubMedGoogle Scholar
  17. 17.
    Graham DY, Klein PD, Evans DJ Jr, et al. Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet. 1987;23:1174–1177.CrossRefGoogle Scholar
  18. 18.
    Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection—a critical review. Aliment Pharmacol Ther. 2004;20:1001–1017.CrossRefPubMedGoogle Scholar
  19. 19.
    Vaira D, Holton J, Menegatti M. Review article: invasive and non-invasive tests for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:13–22.CrossRefPubMedGoogle Scholar
  20. 20.
    Garza-González E, Perez-Perez GI, Maldonado-Garza HJ. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014;20:1438–1449.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sharma BK, Santana IA, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J. 1984;289:717–719.CrossRefGoogle Scholar
  22. 22.
    Shirin H, Levine A, Shevah O, et al. Eradication of Helicobacter pylori can be accurately confirmed 14 days after termination of triple therapy using a high-dose citric acid-based 13C urea breath test. Digestion. 2005;71:208–212.CrossRefPubMedGoogle Scholar
  23. 23.
    Savarino V, Bisso G, Pivari M, et al. Effect of gastric acid suppression on 13C-urea breath test: comparison of ranitidine with omeprazole. Aliment Pharmacol Ther. 2000;14:291–297.CrossRefPubMedGoogle Scholar
  24. 24.
    Cutler AF, Elnaggar M, Brooks E, et al. Effect of standard and high dose ranitidine on 13C-urea breath test results. Am J Gastroenterol. 1998;93:1297–1299.CrossRefPubMedGoogle Scholar
  25. 25.
    Connor SJ, Ngu MC, Katelaris PH. The impact of short-term ranitidine use on the precision of the 13C-urea breath test in subjects infected with Helicobacter pylori. Eur J Gastroenterol Hepatol. 1999;11:1135–1138.CrossRefPubMedGoogle Scholar
  26. 26.
    Rektorschek M, Weeks D, Sachs G, et al. Influence of pH on metabolism and urease activity of Helicobacter pylori. Gastroenterology. 1998;115:628–641.CrossRefPubMedGoogle Scholar
  27. 27.
    Scott DR, Marcus EA, Weeks DL, et al. Mechanisms of acid resistance due to the urease system of Helicobacter pylori. Gastroenterology. 2002;123:187–195.CrossRefPubMedGoogle Scholar
  28. 28.
    Meyer-Rosberg K, Scott DR, Rex D, Melchers K, et al. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology. 1996;111:886–900.CrossRefPubMedGoogle Scholar
  29. 29.
    Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339:412–420.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Scott DR, Munson KB, Marcus EA, et al. The binding selectivity of vonoprazan (TAK-438) to the gastric H + , K + -ATPase. Aliment Pharmacol Ther. 2015;42:1315–1326.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231–238.CrossRefPubMedGoogle Scholar
  32. 32.
    Matsukawa J, Hori Y, Nishida H, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81:1145–1151.CrossRefPubMedGoogle Scholar
  33. 33.
    Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. Epub. 03/02/2016.Google Scholar
  34. 34.
    Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685–695.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685–695.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43:1048–1059.CrossRefPubMedGoogle Scholar
  37. 37.
    Hunt RH, Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Transl Gastroenterol. 2015;6:e119.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter. 1998;3:21–27.CrossRefPubMedGoogle Scholar
  39. 39.
    Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects—a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719–730.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Mayu Takimoto
    • 1
  • Toshihiko Tomita
    • 1
    Email author
  • Takahisa Yamasaki
    • 1
  • Shota Fukui
    • 1
  • Masato Taki
    • 1
  • Takuya Okugawa
    • 1
  • Takashi Kondo
    • 1
  • Tomoaki Kono
    • 1
  • Katsuyuki Tozawa
    • 1
  • Eitatsu Arai
    • 2
  • Yoshio Ohda
    • 1
  • Tadayuki Oshima
    • 1
  • Hirokazu Fukui
    • 1
  • Jiro Watari
    • 1
  • Hiroto Miwa
    • 1
  1. 1.Division of Gastroenterology, Department of Internal MedicineHyogo College of MedicineNishinomiyaJapan
  2. 2.Department of Internal MedicineNishinomiya Kyoritsu Neurosurgical HospitalNishinomiyaJapan

Personalised recommendations